264 related articles for article (PubMed ID: 24338935)
1. Resistant hypertension optimal treatment trial: a randomized controlled trial.
; Krieger EM; Drager LF; Giorgi DM; Krieger JE; Pereira AC; Barreto-Filho JA; da Rocha Nogueira A; Mill JG
Clin Cardiol; 2014 Jan; 37(1):1-6. PubMed ID: 24338935
[TBL] [Abstract][Full Text] [Related]
2. Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment).
Krieger EM; Drager LF; Giorgi DMA; Pereira AC; Barreto-Filho JAS; Nogueira AR; Mill JG; Lotufo PA; Amodeo C; Batista MC; Bodanese LC; Carvalho ACC; Castro I; Chaves H; Costa EAS; Feitosa GS; Franco RJS; Fuchs FD; Guimarães AC; Jardim PC; Machado CA; Magalhães ME; Mion D; Nascimento RM; Nobre F; Nóbrega AC; Ribeiro ALP; Rodrigues-Sobrinho CR; Sanjuliani AF; Teixeira MDCB; Krieger JE;
Hypertension; 2018 Apr; 71(4):681-690. PubMed ID: 29463627
[TBL] [Abstract][Full Text] [Related]
3. Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension.
Williams B; MacDonald TM; Caulfield M; Cruickshank JK; McInnes G; Sever P; Webb DJ; Salsbury J; Morant S; Ford I; Brown MJ
BMJ Open; 2015 Aug; 5(8):e008951. PubMed ID: 26253568
[TBL] [Abstract][Full Text] [Related]
4. Salt, the renin-angiotensin-aldosterone system and resistant hypertension.
Shimosawa T
Hypertens Res; 2013 Aug; 36(8):657-60. PubMed ID: 23912973
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.
Pisoni R; Acelajado MC; Cartmill FR; Dudenbostel T; Dell'Italia LJ; Cofield SS; Oparil S; Calhoun DA
J Hum Hypertens; 2012 Aug; 26(8):502-6. PubMed ID: 21677673
[TBL] [Abstract][Full Text] [Related]
6. Drug therapy for the patient with resistant hypertension.
Donazzan L; Ewen S; Papademetriou V; Linicus Y; Linz D; Böhm M; Mahfoud F
Future Cardiol; 2015 Mar; 11(2):191-202. PubMed ID: 25760878
[TBL] [Abstract][Full Text] [Related]
7. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
[TBL] [Abstract][Full Text] [Related]
8. Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension.
Azizi M; Perdrix L; Bobrie G; Frank M; Chatellier G; Ménard J; Plouin PF
J Hypertens; 2014 Oct; 32(10):2038-44; discussion 2044. PubMed ID: 24983187
[TBL] [Abstract][Full Text] [Related]
9. S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial.
Jo SH; Park SJ; Kim EJ; Kim SJ; Cho HJ; Song JM; Shin J; Park JJ; Shin JH; Han KR; Choi DJ
Trials; 2018 Jun; 19(1):324. PubMed ID: 29925421
[TBL] [Abstract][Full Text] [Related]
10. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J
Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria.
Ando K; Ohtsu H; Arakawa Y; Kubota K; Yamaguchi T; Nagase M; Yamada A; Fujita T;
Hypertens Res; 2010 Jun; 33(6):616-21. PubMed ID: 20379190
[TBL] [Abstract][Full Text] [Related]
12. HYT-hypertension in Turkey: a cross-sectional survey on blood pressure control with calcium channel blockers alone or combined with other antihypertensive drugs.
Seravalle G; Koylan N; Nalbantgil I; Caglar N; Quarti-Trevano F; Makel W; Grassi G; Fici F
High Blood Press Cardiovasc Prev; 2015 Jun; 22(2):165-72. PubMed ID: 25900022
[TBL] [Abstract][Full Text] [Related]
13. Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction.
Rossignol P; Claggett BL; Liu J; Vardeny O; Pitt B; Zannad F; Solomon S
Am J Hypertens; 2018 Mar; 31(4):407-414. PubMed ID: 29228101
[TBL] [Abstract][Full Text] [Related]
14. Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension.
Tsujimoto T; Kajio H
J Am Heart Assoc; 2020 Dec; 9(23):e018827. PubMed ID: 33222584
[TBL] [Abstract][Full Text] [Related]
15. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.
Yugar-Toledo JC; Modolo R; de Faria AP; Moreno H
Vasc Health Risk Manag; 2017; 13():403-411. PubMed ID: 29081661
[TBL] [Abstract][Full Text] [Related]
16. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.
Williams B; MacDonald TM; Morant SV; Webb DJ; Sever P; McInnes GT; Ford I; Cruickshank JK; Caulfield MJ; Padmanabhan S; Mackenzie IS; Salsbury J; Brown MJ;
Lancet Diabetes Endocrinol; 2018 Jun; 6(6):464-475. PubMed ID: 29655877
[TBL] [Abstract][Full Text] [Related]
17. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
18. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.
Volpe M; Tocci G
Vasc Health Risk Manag; 2012; 8():371-80. PubMed ID: 22745561
[TBL] [Abstract][Full Text] [Related]
19. Screening Rates for Primary Aldosteronism in Resistant Hypertension: A Cohort Study.
Jaffe G; Gray Z; Krishnan G; Stedman M; Zheng Y; Han J; Chertow GM; Leppert JT; Bhalla V
Hypertension; 2020 Mar; 75(3):650-659. PubMed ID: 32008436
[TBL] [Abstract][Full Text] [Related]
20. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
Sato A; Suzuki Y; Saruta T
Hypertens Res; 1999 Mar; 22(1):17-22. PubMed ID: 10221346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
